http://db.idrblab.net/ttd/data/target/details/t20248 WebOct 17, 2024 · Difelikefalin (Korsuva™) is a synthetic peptide agonist of the kappa opioid receptor being developed by Cara Therapeutics for the treatment of pruritus. In August 2024, intravenous difelikefalin was approved in the USA for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing haemodialysis.
Bevacizumab - Genentech/Roche - AdisInsight - Springer
WebAddis Insight is Ethiopia’s fastest growing digital news platform, providing consumers with the latest news from Ethiopia and its diaspora. We provide …. See more. 124,692 people … WebOct 31, 2024 · Savolitinib (Orpathys ®; Hutchmed (China) Ltd., AstraZeneca) is a receptor tyrosine kinase mesenchymal epithelial transition factor (c-MET) inhibitor being developed for the treatment of metastatic non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma (RCC), gastric cancer and colorectal cancer. mgt chassis
Zimberelimab: First Approval - figshare
WebYour complete pharma discovery platform connecting information on drug development, clinical trials, safety, commercial deals and patents. See the bigger picture of the drug … WebMar 27, 2024 · Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address. Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. WebPembrolizumab in combination with lenvatinib [see Adis Insight Drug profile 800019249] is approved for first-line treatment of renal cell carcinoma in the US, Norway, Iceland and Lichtenstein and EU. It is approved for head and neck cancer treatment in China. Pembrolizumab is under regulatory review as monotherapy for endometrial carcinoma in ... how to calculate swap ratio in merger